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Abstract: Acute kidney injury (AKI) can potentially lead to the accumulation of antimicrobial
drugs with significant renal clearance. Drug dosing adjustments are commonly made using the
Cockcroft-Gault estimate of creatinine clearance (CLcr). The Modified Jelliffe equation is significantly
better at estimating kidney function than the Cockcroft-Gault equation in the setting of AKI.
The objective of this study is to assess the degree of antimicrobial dosing discordance using
different glomerular filtration rate (GFR) estimating equations. This is a retrospective evaluation of
antimicrobial dosing using different estimating equations for kidney function in AKI and comparison
to Cockcroft-Gault estimation as a reference. Considering the Cockcroft-Gault estimate as the criterion
standard, antimicrobials were appropriately adjusted at most 80.7% of the time. On average, kidney
function changed by 30 mL/min over the course of an AKI episode. The median clearance at the peak
serum creatinine was 27.4 (9.3–66.3) mL/min for Cockcroft Gault, 19.8 (9.8–47.0) mL/min/1.73 m2
for MDRD and 20.5 (4.9–49.6) mL/min for the Modified Jelliffe equations. The discordance rate
for antimicrobial dosing ranged from a minimum of 8.6% to a maximum of 16.4%. In the event of
discordance, the dose administered was supra-therapeutic 100% of the time using the Modified Jelliffe
equation. Use of estimating equations other than the Cockcroft Gault equation may significantly alter
dosing of antimicrobials in AKI.
Keywords: acute kidney injury; Cockcroft Gault; Jelliffe; MDRD; drug dosing; antimicrobials
1. Introduction
Acute kidney injury (AKI) has been reported to occur in approximately 6% of hospitalized
patients [1]. Among patients admitted with AKI, infection is present in approximately 18% [2].
AKI is particularly common among critically ill patients and has been associated with increased
morbidity and significant in-hospital mortality [2,3]. A decline in kidney function can potentially lead
to the accumulation of antimicrobial and other therapeutic agents, with resultant adverse effects [4].
An accurate assessment of kidney function is important in order to optimize drug administration in
this population [5–7].
J. Clin. Med. 2018, 7, 211; doi:10.3390/jcm7080211 www.mdpi.com/journal/jcm
J. Clin. Med. 2018, 7, 211 2 of 10
The most accurate way to determine glomerular filtration rate (GFR) in chronic kidney disease
(CKD) is by formal measurement using an intravenous injection of inulin or a radioisotope and
subsequently collecting urine and serum samples at timed intervals [8,9]. However, the direct
measurement of GFR is cumbersome, expensive and time consuming, and rarely performed in the
acute hospital setting. These procedures are even more complicated in AKI. Pharmacists generally
employ the Cockcroft-Gault (CG) equation to estimate kidney function, altering either or both the
dose and frequency of drugs based on varying degrees of evidence in the setting of impaired kidney
function and/or dialysis [10–16].
Several newer GFR estimating equations have been developed and used widely in epidemiological
studies and clinical practice, including the Modification of Diet in Renal Disease (MDRD) study
equation and the CKD-EPI equation. These equations were derived from varying populations who
generally had stable kidney function. For example, the CG equation was derived from a hospitalized
population including predominantly Caucasian men with stable serum creatinine concentrations
(Scr) [17]. The MDRD study and CKD-EPI equations were largely derived from ambulatory populations
with mild to moderate CKD and relatively stable Scr [12]. Additionally, acute changes in the Scr can
invalidate conventional estimates of kidney function, where the estimates depend on the assumption
that function is at steady state [18]. The Jelliffe equation was developed to estimate GFR in AKI,
where kidney function is not in steady state [19]. Bouchard and colleagues demonstrated that the
Jelliffe equation, modified by consideration of patient volume status, provided a more reliable and
accurate assessment of kidney function when compared with timed urine collections in AKI [20].
While several studies have evaluated CG compared to MDRD estimates in patients with CKD, there is
a paucity of data comparing whether alternative GFR estimating equations might alter dosing of
drugs in AKI [11,21]. The objective of this study was to compare the theoretical influence of different
estimating equations on drug dosing of antimicrobials in patients with AKI.
2. Experimental Section
The Program to Improve Care in Acute Renal Disease (PICARD) group included five academic
medical centers in the United States. The study was approved by the ethics committees at each
participating clinical site. A total of 618 subjects were enrolled over a 31-month period (February 1999
to August 2001), among who 398 required IHD or CRRT. We conducted a retrospective chart review
of antimicrobial dosing for a subset of patients from one center in the PICARD data set. Complete
descriptions of PICARD methods have been previously published [2,3].
AKI was defined differently depending on the baseline Scr. In patients with baseline Scr < 1.5 mg/dL,
AKI was defined as an increase in Scr≥ 0.5 mg/dL, whereas in those with baseline Scr≥ 1.5 mg/dL and
≤ 5 mg/dL, as an increase in Scr≥ 1 mg/dL. Patients with a baseline Scr > 5 mg/dL were not considered
for study inclusion. Pertinent data elements from PICARD used for these analyses included age,
sex, height, weight (to calculate body surface area), daily fluid balance, daily Scr and all dates on which
patients received intermittent hemodialysis (IHD) or continuous renal replacement therapy (CRRT).
For inclusion in this study, patients were required to have complete laboratory information and
must have received antimicrobials during some dates of enrollment in the PICARD study. We excluded
the time period during which patients were on IHD or CRRT, including the days before and after
dialysis. Drug dispensation records were retrieved electronically and included antibiotic name, dose,
frequency, route, start and stop dates.
2.1. Estimation of GFR Using Cockroft-Gault, MDRD, Jelliffe and Modified Jelliffe Equations
Estimations of CLcr or GFR using CG [17], abbreviated MDRD (age, race, gender and Scr) [10],
MDRD adjusted for BSA, Jelliffe [19] and Modified Jelliffe equations [20] were calculated for each
patient during each date of admission that they received an antimicrobial agent (Table 1). For the CG
equation, total body weight was used if this weight was less than 130% of ideal body weight. If total
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body weight was greater than 130% of ideal body weight, an adjusted body weight was calculated by
adding 40% of the difference between the total and ideal body weights to the ideal body weight.
Table 1. Equations used to estimate renal function.
Name Equation
Cockcroft Gault CLcr = ((140 – age) × weight (kg))/(72 × Scr (mg/dL))Multiply by 0.85 if female
MDRD GFR = 186 × (SCr (mg/dL))
–1.154 × (age (years))–0.203 × (0.742 if patient is female) × (1.21 if patient
is black)
MDRD adjusted for BSA GFR = MDRD × BSA / 1.73 m2
Jelliffe (((Volume of distribution × (Scr on day 1 – Scr on day 2)) + creatinine production) ×100/1440/average Scr
Modified Jelliffe
Substitute Adjusted SCr into Jelliffe equation
Adjusted SCr = SCr (measured) × Correction Factor
Correction Factor = ((admit weight (kg) × 0.6) + Sum (Daily fluid balance))/admit weight × 0.6
CLcr = creatinine clearance, MDRD = modification of diet in renal disease, GFR = glomerular filtration rate,
BSA = body surface area.
Clearances were calculated at the peak and nadir Scr values to describe the severity and resolution
of the AKI. The CG equation was used as the reference estimate for the analysis, as the CG equation is
the most frequently used equation by pharmacists for drug dosing [18]. Timed urine collections were
performed as part of routine medical care for a small subset of patients and the duration ranged from
4 to 24 h.
2.2. Evaluation of the Discordance in Drug Dosing Among Estimating Equations
Institutional guidelines from the University of California, San Diego on drug dosing in patients
with impaired kidney function were utilized to assess dose appropriateness. These guidelines
suggest using the CG equation for drug dosing and are based on modified FDA recommendations.
An antimicrobial episode was defined as each day that the patient received the antimicrobial or
any time the antimicrobial was altered (e.g., change in antimicrobial dose or frequency). The rate
of discordance in drug dosing was calculated as the difference in the number of correctly dosed
antimicrobial episodes between the CG and the other estimating equations (Table 1) divided by the
total number of antimicrobial episodes (Equation (1)).
(#Correct Episodes CG - #Correct Episodes comparison) × 100
Total #Episodes
(1)
We used antimicrobial episodes for calculating discordance since a single patient may receive
numerous antimicrobials for varied durations of therapy. Additionally, the potential for error could be
different depending on the antimicrobial and dosing range. A chi square test of independence with
Bonferroni correction for multiple comparisons was used to assess if there was a difference in number
of antimicrobial episodes dosed correctly between estimating equations for each antimicrobial (R 2.8.1).
Two-tailed p-values < 0.05 were considered statistically significant.
3. Results
A total of 719 antimicrobial episodes from 32 unique patients were included in the analysis.
The median age was 49.5 (range 31 to 89) years, 12.5% had CKD and the most common etiology of AKI
was acute tubular necrosis (ATN). Demographic characteristics are summarized in Table 2.
Daily Scr values were used to estimate clearance for the entire cohort (Table 3). In order to show
the spectrum of AKI, we calculated the median clearance at peak and nadir Scr and this ranged from
19.8 to 27.4 and 46.9 to 58.8 mL/min, respectively (Figures 1 and 2). During the course of AKI, there was
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a clinically meaningful change in kidney function of approximately 30 mL/min, which would indicate
the need for re-evaluation of drug dosing.
Table 2. Demographics.
Variable n (%) or Median (Range)
Age (years) 49.5 (31–89)
Gender
Male 14 (44%)
Female 18 (56%)
Weight (kg) 73.9 (45–99)
Height (cm) 169 (152–191)
BSA (m2) 1.81 (1.38–2.26)
APACHE III Score * 90 (38–151)
History of CKD 4 (12.5)
Etiology of AKI
ATN 14 (44%)
Nephrotoxicity 2 (6%)
Multifactorial 11 (34%)
Hepatorenal 3 (10%)
Prerenal 2 (6%)
* APACHE III scores available for 30 patients.
Table 3. Clearance estimates.
Parameter Timed UrineCollection
CG
(mL/min)
MDRD
(mL/min/1.73 m2)
MDRD – Adj BSA
(mL/min)
Jelliffe
(mL/min)
Modified Jelliffe
(mL/min)
CL peak Scr
Median (range) -
27.4
(9.3–66.3) 19.8 (9.8–47.0) 21.2 (9.9–60.4)
21.2
(5.2–56.4) 20.5 (4.9–49.6)
CL Nadir Sc
rMedian (range) -
58.8
(18.4–88.9) 46.9 (24.8–85.8) 50.8 (22.0–92.1)
52.8
(17.3–79.0) 47.2 (14.3–79.0)
Median CL
(range) 22.8 (13.4–26.2)
34.4
(9.3–88.9) 28.6 (9.8–85.8) 29.3 (9.9–92.1)
30.3
(4.5–78.9) 26.7 (4.6–78.9)
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at the time of injury recovery using the lowest serum creatinine value in each estimating equation.
3.1. Overall Impact on Drug Dosing Based on Individual Equations
Patients received at least one or more of the following antimicrobials whose disposition is
influenced by kidney function: ampicillin, cefazolin, ceftazidime, ciprofloxacin, fluconazole, ganciclovir,
metronidazole, piperacillin/tazobactam. Of the 719 dosing episodes, the appropriate dose of
antimicrobials was administered at most 81% of the time (Table 4). Seventeen patients received a
total of 139 episodes of inappropriate doses according to the CG equation, but after removing these
inappropriate doses, 30 patients and 580 episodes remained. The discordance rate between the CG
equation and the other estimation equations ranged from a minimum of 9% to a maximum of 16%
(Table 4).
Table 4. Dose appropriateness for all drugs.
Estimating
Equation
Number Dosed Correct (%)
n = 719 episodes (32 patients)
Discordance Rate (%) Number Dosed Correct (%)
n = 580 episodes (30 patients)
Discordance Rate (%)
CG 580 (81) - 580 (100) -
MDRD 529 (74) 7 515 (89) 11
MDRD BSA 531 (74) 7 526 (91) 9
Jelliffe 531 (74) 7 530 (91) 9
Mod Jelliffe 488 (68) 12 485 (84) 16
3.2. Breakdown of Impact on Drug Dosing Based on Drug Administered
The most commonly prescribed drugs in our study population were ceftazidime, ciprofloxacin
and fluconazole with 69%, 66% and 47% of patients receiving these medications. In the majority of
cases, the discordance between estimating equations was statistically significant. The discordance rate
for all episodes varied among the antimicrobial agents from 6 to 22% (Table 5).
J. Clin. Med. 2018, 7, 211 6 of 10
Table 5. Dose appropriateness for specific antimicrobials.
Drug # Patients
Received (%)
# Correct CG (%) # Correct
Mod-Jelliffe (%)
Discordance
Rate (%)
p Value
All drugs - 580/719 488/719 13 <0.001
Ceftazidime 22 (69) 140/200 (70) 107/200 (54) 16 0.009
Ciprofloxacin 21 (66) 164/170 (96) 153/170 (90) 6 -
Fluconazole 15 (47) 104/129 (81) 91/129 (71) 10 -
Metronidazole 11 (34) 52/52 (100) 45/52 (87) 14 -
Cefazolin 7 (22) 31/36 (86) 23/36 (64) 22 -
Ganciclovir 7 (22) 59/92 (64) 41/92 (45) 20 -
Ampicillin 4 (13) 10/16 (63) 9/16 (56) 6 -
Piperacillin/
Tazobactam
4 (13) 16/16 (100) 15/16 (94) 6 -
The discordance in drug dosing between the CG and the Modified Jelliffe was highest for cefazolin
(22%), ganciclovir (20%) and ceftazidime (16%). In patients who were not dosed correctly according to
CG, we did not find any episodes of under-dosing. We analyzed the direction of error in dosing in the
subset of episodes where the dose was correct based on the CG estimate of clearance (Table 6).
Table 6. Correct doses for Cockcroft Gault but overdosing for modified Jelliffe.
Antimicrobial Numberof Patients
Number
of Dosing
Episodes
Number of
Overdosing
Episodes
Median Daily Dose
(Range)
Median Overdoseper Day
(Range)
Acyclovir 2 4 0 2400 mg 0 mg
Ampicillin 3 10 1 3500 mg (3000–8000) 5000 mg
Cefazolin 7 31 7 3000 mg (2000–3000) 1000 mg
Ceftazidime 20 140 33 2000 mg (500–3000) 1000 mg (500–3000)
Ciprofloxacin 24 164 11 500 mg (400–1500) 400 mg (200–500)
Fluconazole 17 104 16 100 mg (50–400) 50 mg (50-100)
Ganciclovir 6 59 18 Oral: 3000 mg (1000–3000)IV: 100 mg (75–400)
Oral: 2000 mg (1000–2000)
IV: 110 mg (45–200)
Metronidazole 11 52 7 1500 mg (1000–1500) 500 mg
Piperacillin/
Tazobactam 4 16 1 11,250 mg (6750–1,3500) 4500 mg
Depending on the frequency of antimicrobial administration, the percentage of over-dosing
episodes was as high as 30%. Furthermore, in reviewing the doses administered, excess doses were
clinically relevant for some antimicrobials (Table 6).
4. Discussion
In our study, we found that patients received an inappropriate dose of antimicrobials in
approximately one in six dosing episodes. Almost half of the patients included in this study experienced
a dosing error. The change in estimated clearance was clinically significant for the majority of patients,
warranting a dosage adjustment of medications. The overall discordance rate between the CG
equation and the other estimating equations was between 9% and 16%. Importantly, the difference in
clearance between the estimating equations was approximately 8 mL/min or a 30% relative difference.
This difference also crossed a cutoff value for our institutional guidelines for dosage adjustment
(30 mL/min) resulting in antimicrobial dosing discordance. This presents a clinical challenge since
physicians and pharmacists are faced with different kidney function estimates, which ultimately lead
to variable doses of critical medications. We found that in cases of discordances between the CG and
Modified Jelliffe equations, the dose of antimicrobial administered was supra-therapeutic when using
the Modified Jelliffe estimate as the reference point.
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Several factors can be attributed to the challenge of drug dosing in AKI. These include the
delayed rise of Scr in response to injury, the accuracy of the various estimating equations in AKI,
the lack of therapeutic drug monitoring for several antimicrobials, as well as the lack of published
pharmacokinetic information on antimicrobial dosing in patients with AKI not receiving dialysis
or hemofiltration.
Estimating kidney function in AKI remains controversial. Hoste and colleagues have demonstrated
that in critically ill patients with normal Scr, urinary excretion of creatinine was markedly reduced [22].
They concluded that using Scr to predict kidney function was insensitive in the critically ill population
and advocated for the use measured CLcr [22]. Clinicians often measure CLcr with urinary collections
since patients may have an indwelling catheter and the collection can be completed by a nurse. However,
urinary CLcrs have been shown to be inaccurate in the critically ill population. Robert and colleagues
published results comparing the performance of 30 min urinary CLcr, 24 h urinary CLcr, and CG estimates
to inulin clearance in 20 critically ill patients with stable Scr whose mean was 1.8 ± 1.5 mg/dL [16].
The 30 min collection performed similarly to the 24 h collection, but in a subset of patients, urinary CLcr
over-predicted GFR by 30–300% [16]. Bragadottir and colleagues demonstrated that urinary CLcr had a
low reproducibility compared to measured GFR [23]. Given the limitations of urinary collections in
the critically ill population, estimating equations are attractive for routine bedside approximations
of GFR. To date there are various studies comparing the ability of estimating equations to accurately
predict measured CLcr or GFR in patients with stable renal function [8–17,24]. Analysis of these studies
indicates that the most accurate equation varies according to the population studied [9,15]. Steady state
equations such as CG will systematically over-estimate clearance and lead to over-dosing episodes in
patients with AKI. Kirwan and colleagues compared the accuracy of the various steady state estimating
equations to measured CLcr (4 h collection) in critically ill patients with AKI. They found that the
accuracy of the various equations within 50% of measured CLcr to be 68, 78 and 81% for the CG,
MDRD and CKD-EPI equations respectively [25]. The performance of these equations was not as good
as in the setting of CKD. Poggio and colleagues examined the accuracy of the CG and MDRD equations
in estimating GFR compared to measured GFR in hospitalized patients with kidney dysfunction [13].
They demonstrated that the MDRD and CG equations over-estimated GFR and the accuracy of the
estimates within 50% of the measured GFR was 49% and 40%, respectively [13]. Bragadottir found
that the MDRD, CKD-EPI and CG equations performed poorly when compared to measured GFR
in critically ill patients with early AKI with biases of 7.39–11.58 mL/min [23]. This bias is consistent
with other studies noting over-estimation of measured CLcr by approximately 6–17 mL/min [25,26].
These steady state equations are problematic for the estimation of kidney function in an intensive care
setting or in AKI.
Non steady state equations such as Jelliffe will provide estimates of GFR that are closer to the
true clearance [19]. Using data from PICARD, Bouchard and colleagues compared the accuracy of
estimating GFR using CG, MDRD, Jelliffe and a modified Jelliffe equation to that of a 24-h measured
urinary CLcr [20]. The authors found that among critically ill patients with AKI, traditional estimating
equations (CG, MDRD) significantly overestimate kidney function compared to a modified Jelliffe
equation adjusted for fluid balance [20].
One limitation of this study was the small sample size of 32 patients, as we could retrieve
antimicrobial dosing data only on a small subset of patients from the PICARD database. In addition,
the retrospective nature of the study is a limitation in capturing the dynamic nature of prescribing and
pharmacist consulting on antimicrobial doses. This safety concern was unanticipated but provides
strong rationale for electronic algorithms for drug dosage adjustments according to kidney function.
Our retrospective study is limited in assessing the validity of the estimating equations for patients
with AKI. We utilized the CG estimate as the criterion standard since this is the most commonly
used equation for adjusting the doses of drugs [18]. We found discordance in kidney function
estimates but we are limited in concluding which equation is most accurate and whether the use
of the Modified Jelliffe equation would have resulted in appropriate antimicrobial concentrations.
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Most clinicians feel that the therapeutic index is wide for many antimicrobials such as penicillins and
cephalosporins. However, inappropriate dosing may contribute to the development of super-infections
and increased costs.
Our study did not include antimicrobials in which therapeutic drug monitoring is available.
If serum concentration monitoring is available, this guides dosage adjustments and little emphasis is
placed on the renal estimating equation. The GFR estimating equations are used to calculate initial
doses and subsequent dosing is based on serum concentrations.
Our study did not include patients on IHD or CRRT. In the setting of dialysis, a fixed clearance is
prescribed. However, estimating CLcr from the prescribed effluent volumes may not be accurate since
the clearance delivered is frequently less than that prescribed [27]. Dosing guidelines for many drugs
in AKI are generally derived from experience in patients with CKD. This may not account for changes
in drug metabolism, tubular function or drug transport in the setting of AKI [28–31]. Applying CLcr
estimates from prescribed effluent volume, utilizing dosing guidelines derived from CKD and a lack
of available therapeutic drug monitoring may create a potential for under-dosing antimicrobials in a
critically ill population receiving IHD or CRRT [32].
The KDIGO position statement on drug dosing considerations indicates there is a lack of
compelling evidence for the superiority of any one estimating equation for drug dosing [18]. The Acute
Disease Quality Initiative (ADQI) recommends the use of short timed urine collections or the modified
Jelliffe equation for estimating kidney function in persistent AKI [33]. Further research is needed on
the quantification of kidney function in persistent AKI in the critically ill population.
5. Conclusions
Critically ill patients with AKI are at risk for significantly increased morbidity and mortality.
It is essential that drugs be dosed as accurately as possible to minimize potential adverse effects and
improve patient outcomes. The observations from our study indicate that there is discordance in drug
dosing when using kidney function estimating equations. Prospective studies evaluating the Modified
Jelliffe equation and other strategies for drug dosing in the setting of AKI should be undertaken.
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